GlassScriptPhysician profile
Sharon P Willis
NPI 1417236845
$3,194.17
in general payments reported to CMS, 2019-2025
25 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.37 · 2023: $847 · 2024: $1,033 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,080 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,079.80 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $394.34 | 2023-2025 | Gemtesa, Aptiom |
| Otsuka America Pharmaceutical, INC. | $387.99 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $283.92 | 2023-2025 | |
| Lundbeck LLC | $256.92 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $226.68 | 2023-2025 | Mounjaro, Emgality, Reyvow |
| Novo Nordisk INC | $201.34 | 2023-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $179.24 | 2022-2025 | |
| Astellas Pharma US INC | $166.47 | 2024-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $140.87 | 2023 | Seglentis, Livalo |
| Astrazeneca Pharmaceuticals LP | $133.95 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Ucb, INC. | $107.09 | 2024 | Nayzilam |
| Glaxosmithkline, LLC. | $94.21 | 2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.66 | 2025 | Caplyta |
| Abbott Laboratories | $83.71 | 2024-2025 | Freestyle Libre 3, Freestyle Libre |
| Idorsia Pharmaceuticals US INC | $82.43 | 2023-2025 | Quviviq, Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $79.75 | 2025 | |
| Ardelyx, INC. | $79.62 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.54 | 2024-2025 | Jardiance, Tradjenta |
| Scilex Pharmaceuticals INC. | $44.18 | 2023 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $35.32 | 2024-2025 | Uzedy, Austedo Xr |
| Xeris Pharmaceuticals, INC. | $17.76 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $16.18 | 2023 | |
| Corcept Therapeutics | $15.36 | 2025 | Korlym |
| Neurelis, INC. | $14.03 | 2024 | Valtoco |
| Pfizer INC. | $13.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.